[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Panafina, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100522297",false,"NCT06080789","A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis","A Phase 2a, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants With Predicted Severe Acute Pancreatitis","Key Inclusion Criteria:\n\n* Diagnosis of acute pancreatitis\n* Predicted severe acute pancreatitis, based on protocol defined criteria\n* Lack of clinically meaningful improvement from status at admission, at the discretion of Investigator, at the time of randomization\n* Suitable for EUS-guided study drug administration procedure\n* Contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) of the abdomen\u002Fpancreas available for the evaluation of exclusion criteria\n\nKey Exclusion Criteria:\n\n* Confirmed severe acute pancreatitis as defined by the Revised Atlanta Classification of Acute Pancreatitis (ie, Persistent \\[\\> 48 hours\\] organ failure, per Modified Marshall Score), prior to randomization\n* Anticipated discharge from hospital within 48 hours of randomization\n* More than 30% pancreatic necrosis on screening CECT or MRI\n* History of previous pancreatic necrosis, including necrosectomy\n* History of calcific chronic pancreatitis\n* Evidence of cholangitis","ALL","18 Years","85 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis.\n\nThe main question the study aims to answer is:\n\n• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis.\n\nThe study also aims to answer:\n\n• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis.\n\nStudy participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only.\n\nThe study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.",[26],"Acute Pancreatitis","RECRUITING","2026-05-26",{"date":30,"type":31},"2026-05-28","ACTUAL",{"date":33,"type":31},"2024-06-28",{"date":35,"type":20},"2026-12",{"name":37,"class":38},"Panafina, Inc.","INDUSTRY",16,""]